Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1935 • ACR Convergence 2024
Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Nelly Ziade¹, Karen Mechleb², Nizar Ani³, avin maroof⁴, ASAL ADNAN RIDHA⁵, Manal El Rakawi⁶, Chafika Haouichat⁶, Bassel Elzorkany⁷, Sherif Gamal⁸, Mariama Erraoui⁹, Manal Al-Mashaleh¹⁰, Fatima Alnaimat¹¹, Basel masri¹², fatemah Baron¹³, Lina El Kibbi¹⁴, Krystel Aouad¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH - ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Baghdad College of Medicine, Baghdad, Iraq, ⁴University of Kurdistan Hawler, Erbil, Iraq, ⁵Baghdad Teaching Hospital, baghdad, Iraq, ⁶Djillali Bounaama University Hospital, Algiers, Algeria, ⁷Private (BZRC), Cairo, Egypt, ⁸Cairo University, Cairo, Egypt, ⁹Souss Massa Univeristy, Rabat, Morocco, ¹⁰Royal Medical Services, Amman, Jordan, ¹¹University of Jordan, Amman, Jordan, ¹²Jordan Hospital and Medical Center, Amman, Jordan, ¹³Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹⁴Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁵Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Early referral of patients with chronic inflammatory rheumatic diseases (CIRDs) to rheumatology is essential to reduce diagnostic delays and improve long-term prognosis. Referral strategies…
Abstract Number: 2140 • ACR Convergence 2024
Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis
Katherine Wysham¹, Hannah Brubeck², Kylie Riggles³, Riley Bass⁴, Elizabeth Wahl², Radhika Narla⁵, Namrata Singh⁶, ariela orkaby⁷, Joshua Baker⁸, Patricia Katz⁹, Dolores Shoback¹⁰ and Jose Garcia¹¹, ¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA Puget Sound Health Care System, Bellevue, WA, ⁴VA Puget Sound Health Care System, Seattle, ⁵VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, ⁶University of Washington, Bellevue, WA, ⁷New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰San Francisco VA/University of California, San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System/University of Washington, Seattle, WA
Background/Purpose: Frailty represents a state of increased vulnerability to poor outcomes after physiologic stressors, and occurs at higher rates and younger ages in RA. Frailty…
Abstract Number: 2220 • ACR Convergence 2024
Outcomes in Seronegative Rheumatoid Arthritis and Undifferentiated Arthritis
Andrew Price, David Mecham, Zachary Kerosky, Joshua Hunt, Anthony Greco and Michael Loncharich, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Seronegative rheumatoid arthritis (SnRA) and undifferentiated arthritis (UA) are heterogeneous conditions that share many clinical features with other systemic rheumatic diseases. Patients initially diagnosed…
Abstract Number: 2237 • ACR Convergence 2024
The Association Between Bariatric Surgery and Incident Rheumatoid Arthritis
Helana Jeries¹, Revital Perlov Gavze², Rula Daood³, Fadi Hassan³, Liat Lev shalem⁴, Ahmad Assalia⁵ and Mohammad E Naffaa³, ¹Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, ²Maccabi Healthcare Services, Tel Aviv, Israel, ³Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, ⁴Maccabi Healthcare Services, Tel Aviv, HaMerkaz, Israel, ⁵Rambam Healthcare Campus, Haifa, HaZafon, Israel
Background/Purpose: Obesity is considered a controversial risk factor for developing rheumatoid arthritis (RA), and the association between weight change and RA incidence is inconclusive. The…
Abstract Number: 2256 • ACR Convergence 2024
Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
Jia Yi Hee¹, Hendrik Nel², Yann Abraham³, Katrina Chakradeo⁴, Michelle Roch⁴, Tom Lynch⁵, Lyn March⁵, Mihir Wechalekar⁶, Helen Keen⁷ and Ranjeny Thomas⁸, ¹The University of Queensland, Woolloongabba, Queensland, Australia, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Janssen Research and Development, Beerse, Belgium, ⁴The University of Queensland, Brisbane, Australia, ⁵The University of Sydney, Sydney, New South Wales, Australia, ⁶Flinders Medical Centre, Adelaide, Australia, ⁷Fiona Stanley Hospital, Murdoch, Western Australia, Australia, ⁸University of Queensland, Brisbane, Australia
Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
Abstract Number: 2275 • ACR Convergence 2024
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Lucia Otero-Varela¹, Carlos Sanchez-Piedra², Elena Rabadán Rubio³, Juan Camilo Sarmiento-Monroy⁴, Chamaida Plasencia-Rodríguez⁵, Diana Sueiro⁶, Olga Martinez⁷, Noemí Busquets Pérez⁸, Mercedes Freire González⁹, Fernando Sánchez-Alonso¹⁰, José María Álvaro-Gracia¹¹ and Isabel Castrejon¹², and BIOBADASER group, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, ³Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁴Hospital Clínic Barcelona, Barcelona, Spain, ⁵Hospital Universitario La Paz, MADRID, Spain, ⁶Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁷Hospital Universitario de Salamanca, Zamora, Spain, ⁸HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁹Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Gregorio Marañón, Madrid, Spain, ¹²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients…
Abstract Number: 2538 • ACR Convergence 2024
HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q);; Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Bunkyo-ku, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The largest genetic risk factor for RA localizes to the MHC Class II HLA-DRB1 gene, which encodes the machinery for antigen presentation to CD4…
Abstract Number: 2613 • ACR Convergence 2024
Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Emily Kowalski³, Xiaosong Wang⁴, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni⁴, Caleb Bolden⁵, Naomi Patel⁵, Krishan Guzzo³, Marcy Bolster⁵, Shruthi Srivatsan⁵, Pierre-Antoine Juge⁶, Tracy J Doyle⁷, Zachary Wallace⁸ and Jeffrey Sparks⁹, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA, ⁸Massachusetts General Hospital, Newton, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…
Abstract Number: 0039 • ACR Convergence 2024
Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum
Lacie Scaletta¹, Teneema Kuriakose¹, Sambit Nanda¹, Mia Collins², Erika Darrah³, Iain McInnes⁴, David Close⁵ and Gary Sims¹, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁵Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) promote inflammation and joint tissue injury and define a poor prognostic group of patients with rheumatoid arthritis (RA). Citrullinated autoantigens…
Abstract Number: 0056 • ACR Convergence 2024
Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Ryo Motoyama¹, Shohei Nakamura¹, Eisuke Inoue², Hideto Takada³, Masayoshi Harigai⁴ and Yuko okamoto¹, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University, Denver, CO, ⁴International University of Health and Welfare, Tokyo, Japan
Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…
Abstract Number: 0139 • ACR Convergence 2024
Analysis of Rheumatoid Arthritis Epidemiology in Mexico Using the GBD 2019 Study and Forecasting Future Trends for 2030 and 2040
CLAUDIA MENDOZA-PINTO¹, IVET ETCHEGARAY MORALES², PAMELA MUNGUIA-REALPOZO¹, Socorro Méndez-Martínez³, Álvaro Montiel-Jarquín¹, Roberto Berra-Romani⁴, Fernanda Solis-Mendoza⁵ and Mario García-Carrasco⁶, ¹Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, ⁴Benemérita Universidad Autónoma de PueblaPueblam, Puebla, Puebla, Mexico, ⁵Universidad de las Américas de Puebla, Puebla, Puebla, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder related to disability and premature mortality. Nowadays, the burden of RA is needed for healthcare…
Abstract Number: 0218 • ACR Convergence 2024
Incidental Findings on Whole Body 18F-FDG PET/CT in a Rheumatoid Arthritis Clinical Trial Population
Christina Costeas¹, Daniel Solomon², Katherine Liao³, Jon Giles⁴, Joan Bathon⁵ and Jane Kang⁶, and the TARGET Trial Consortium, ¹Columbia University Irving Medical Center, New York, NY, ²Brigham and Women's Hospital, Newton, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Columbia University, NEW YORK, NY, ⁶Columbia University Medical Center, New York, NY
Background/Purpose: Performing whole body imaging inevitably reveals incidental findings in the majority of cases. A clinical trial was conducted to determine whether different treatment strategies…
Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0460 • ACR Convergence 2024
Cartilage Damage or (sub)luxation of Finger Joints: Impact on Physical Function in Patients with Rheumatoid Arthritis
Takehisa Ogura¹, Yasuto Minegishi², Chihiro Imaizumi¹, Reina Maezawa¹, Takaharu Katagiri¹ and Hideto Kameda¹, ¹Toho university, Tokyo, Japan, ²Toho University, Tokyo
Background/Purpose: It has been reported that radiographic joint space narrowing (JSN) score affects the health assessment questionnaire-disability index (HAQ-DI) score in rheumatoid arthritis (RA) patients.…
Abstract Number: 0476 • ACR Convergence 2024
Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Alejandro Valero Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, María Martín López⁶, Santos Castañeda⁷, Jesús Loarce⁸, César Antonio Egües Dubuc⁹, Natalia Mena Vázquez¹⁰, Carmen Carrasco-Cubero¹¹, Carolina Perez-Garcia¹², Juan M Blanco Madrigal¹³, Nuria Vegas Revenga¹⁴, Lorena Pérez Albadalejo¹⁵, Rafaela Ortega-Castro¹⁶, Desiree Palma¹⁷, Ana Fernández-Ortiz¹⁸, Maria López Lasanta¹⁹, Marta Garijo Bufort²⁰, Ivette Casafont-Sole²¹, Andrea García-Valle²², Maria Paz Martinez-Vidal²³, Bryan Josué Flores Robles²⁴, EVELIN CERVANTES PEREZ²⁵, Ignacio Brana Abascal²⁶, Sara María Rojas Herrera²⁷, Juan Camilo Sarmiento-Monroy²⁸, Virginia Ruiz-Esquide²⁹, JOSE RAMON LAMUA RIAZUELO³⁰, Uxue Astigarraga-Urquia³¹, Diego Ferrer³² and Ricardo Blanco-Alonso³³, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Zumarraga Hospital, Zumarraga, Spain, ⁴Hospital de Jeréz de la Frontera, Cadiz, Spain, ⁵CHU Ourense, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, ¹⁰IBIMA, Málaga, Andalucia, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, ¹⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁵Hospital Universitario de Jaén, Jaén, Spain, ¹⁶Hospital Reina Sofía, Cordoba, Andalucia, Spain, ¹⁷Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁹Hospital Vall d�Hebron, Barcelona, Spain, ²⁰Hospital de Sagunto, Valencia, Spain, ²¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²²Hospital General Río Carrión, Palencia, Spain, ²³Hospital San Juan de Alicante, Alicante, Spain, ²⁴Hospital San Pedro, Logroño, Spain, ²⁵Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ²⁷Hospital de Mérida, Badajoz, Spain, ²⁸Hospital Clínic Barcelona, Barcelona, Spain, ²⁹Hospital Clinic de Barcelona, Barcelona, Spain, ³⁰Hospital Universitario del Henares, Madrid, Spain, ³¹Hospital Universitario de Navarra, Pamplona, Spain, ³²Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].